Abstract
Background Although crucial to the success of the US healthcare system, generic medication is not without some risks, especially when a transition is made midtreatment from a brand-name formulation to its generic counterpart. Thankfully, such a transition is usually orderly and unnoticed, without disruption to the treatment; however, this is not always the case.
Case Report This case study details an example of 1 such unfortunate disruption to treatment. A stable patient with schizophrenia was switched from brand-name Zyprexa to generic olanzapine. Within several months of the switch, the patient suffered a marked grayish discoloration of his teeth. His medication regimen was then transitioned from generic olanzapine to a new but different brand-name medication (Abilify). The transition was a success, with resolution of the adverse effect and continued stability of his mental state.
Conclusion Generic olanzapine was introduced to the market in fall 2011. It remains to be seen whether this adverse effect was simply an anomaly or the beginning of a more ominous trend.
Footnotes
The author has no financial or proprietary interest in the subject matter of this article.
- © Academic Division of Ochsner Clinic Foundation